Janssen Alzheimer Immunotherapy Research & Development LLC
🇺🇸United States
Clinical Trials
9
Active:0
Completed:5
Trial Phases
2 Phases
Phase 2:5
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (62.5%)Phase 3
3 (37.5%)Retrieval of Patient Information After Discontinuation
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-09-02
- Target Recruit Count
- 169
- Registration Number
- NCT01658722
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2015-01-05
- Target Recruit Count
- 126
- Registration Number
- NCT01284387
- Locations
- 🇺🇸
Janssen AI Investigational Site, Oklahoma City, Oklahoma, United States
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2014-05-09
- Target Recruit Count
- 146
- Registration Number
- NCT01254773
- Locations
- 🇺🇸
Janssen AI Investigational Site, Providence, Rhode Island, United States
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2013-12-20
- Target Recruit Count
- 896
- Registration Number
- NCT00937352
- Locations
- 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸Dedicated Clinical Research, Inc., Goodyear, Arizona, United States
🇺🇸Banner Alzheimer's Institute, Phoenix, Arizona, United States
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 194
- Registration Number
- NCT00606476
- Locations
- 🇺🇸
Janssen AI Investigational Site, Seattle, Washington, United States
- Prev
- 1
- 2
- Next
News
No news found